Shield Therapeutics PLC (LON:STX) had its price objective boosted by Canaccord Genuity from GBX 235 ($3.07) to GBX 241 ($3.15) in a research note published on Tuesday morning. They currently have a buy rating on the stock.

Separately, Liberum Capital reaffirmed a buy rating and set a GBX 310 ($4.05) price target on shares of Shield Therapeutics PLC in a research note on Tuesday.

Shares of Shield Therapeutics PLC (LON:STX) opened at 162.50 on Tuesday. The stock’s 50 day moving average is GBX 156.62 and its 200 day moving average is GBX 165.98. The stock’s market capitalization is GBX 175.72 billion. Shield Therapeutics PLC has a 52-week low of GBX 147.00 and a 52-week high of GBX 190.00.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.